

## Webinar on IMI 2 – IMI2 - Call 21 webinar: Fast-track Call on the novel coronavirus (COVID-19)

### Participant list

04.03.2020

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Álvaro	Aceña	IIS Fundación Jiménez Díaz	Spain	aacena@fjd.es	I would bring to the project a randomized study with statins in patients with coronavirus infection or at risk of infection. The beneficial effects of statins are not only cholesterol reduction, but that they have immunomodulatory and anti-inflammatory properties. Furthermore, cholesterol allows invasion by pathogens by acting as a docking site for the internalization of virus. We have a preeliminary data (under review in this moment) in which statin use was associated with mortality benefit in patients with a Respiratory Virus Infection confirmed by laboratory tests in our center. So we think statins could provide a useful option for the treatment of Virus Infections in the future.
David	Alexander	Ontera	USA	david.alexander@ontera.bio	Ontera brings a field deployable platform based around a solid state nanopore sensor to quantitative NAT, serology and urinalysis testing.
Anna	Artese	Net4Science academic Spin-Off, Università degli Studi	Italy	artese@unicz.it	Net4Science would be useful for the rational drug design of new potential antiviral agents as a link between public and private research institutions.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
		"Magna Græcia" di Catanzaro			
Emelia	Assar	public health england	porton down	emelia.assar@phe.gov.uk	I have recently joined PHE NIS Business Development team
Zeynep	Atabay Taskent	atabay	Istanbul	zatabay@atabay.com	cov
Sigrid	Auweter	Smart Reporting GmbH	Germany	s.auweter@smartreporting.de	Develop reporting and decision support for fast and accurate analysis of COVID-19 profiles on CT/biopsy, in line with diagnostic criteria.
Giuseppe	Balistreri	University of Helsinki	Helsinki	giuseppe.balistreri@helsinki.fi	Virologist, high-content imaging, virus-cell interactions, genome-wide CRISPR screening, novel antiviral molecules
Anne	Balkema-Buschmann	Friedrich-Loeffler-Institut (FLI) Institute of Novel and Emerging Infectious Diseases	Germany	anne.buschmann@fli.de	<p>The Friedrich-Loeffler-Institut is running animal facilities for small and large animals up to biosafety level 4. FLI staff has decades of experience in working with animal disease and zoonotic agents in a variety of relevant animal species. I am the person responsible for the maintenance of FLI's fruit bat colonies of two different species (<i>Rousettus aegyptiacus</i> and <i>Eidolon helvum</i>) that are available for challenge and pathogenesis studies.</p> <p>The transmissibility to domestic animals and wildlife species, as well as their potential role in the epidemiology of COVID-19 is one of our major interests and competences in the field of Sars-COV-2 research.</p>

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Robert	Bals	Saarland University	Germany	Robert.Bals@uks.eu	High throuput assays on differentiated airway epithelium for detection of novel antivirals.
Sofiane	Bennacer	Credo Diagnostics Biomedical	Singapore	s.bennacer@credodxbiomed.com	We have developed a 20 min COVID-19 RT-PCR test. It can be deployed without additional equipment in laboratories, ER, clinics, and even in airports and seaports.
Natalia	Beshchasna	Fraunhofer Institute for Ceramic Technologies and Systems	Germany	natalia.beshchasna@ikts.fraunhofer.de	IKTS develops (bio)sensors based on LTTC, glass, flexible substrates and printing technologies; works in the field of microfluidics, collaborates with companies in the area of in vitro diagnostics, aptamer development, microfluidic devices, precise electronics; currently works in two international Eureka consortiums developing aptamer-based biosensors.
Charles	Betz	Luxinnovation - National Innovation Agency	Luxembourg	charles.betz@luxinnovation.lu	Contact to national stakeholders (companies, public research, NGOs)
Jane	Boland	St George's, University of London	London	jboland@sgul.ac.uk	Adminstrative, legal, financial and project management experience
Luisa	Borgianni	Sclavo Vaccines Association	SIENA	borgianni@sclavo.org	Management, Dissemination and Impact assesment

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Annalaura	Brai		Italy	al.brai@leaddiscoverysiena.it	Custom synthesis of compounds, internal library of antivirals
Andrea	Calcagno	Unit of Infectious Diseases, Department of Medical Sciences, University of Torino	Italy	andrea.calcagno@unito.it	We are a Unit of Infectious Diseases currently admitting and following patients with infection by SARS-CoV-2. We have a strong pharmacological background and we are able to develop methods for measuring drugs PK in plasma and tissues. We therefore may contribute by enrolling patients and/or by performing PK/PD studies.
Marc	Centellas	Laboratorios Gebro Pharma, S.A.	Spain	marc.centellas@gebro.es	Gebro developed Duplaxil, a hydroxychloroquine 400mg film-coated tablets. This product inhibits key components of the coronavirus infection lifecycle.
Corentin	Chaboud	BIOASTER	France	Corentin.chaboud@bioaster.org	Rapid diagnostic test development, antigen/antibody development, industrial standards, IMI project experience.
Gael	Champier	ArkAb SAS	France	gael.champier@arkab.fr	ArkAb will develop Human chimeric mAbs for oral immunotherapy anti 2019-nCov (secretory IgA) and for immunodiagnosis (IgM, IgA and IgA).
Ming-Fu	Chang	National Taiwan University	Taipei	mfchang@ntu.edu.tw	We would like to develop rapid tests for COVID-19 patients.
Chien-Fu	Chen	National Taiwan University	Taiwan	stevechen@ntu.edu.tw	Develop COVID-19 rapid test platforms.
Florence	Chung	Inserm Transfert	France	florence.chung@inserm-transfert.fr	Project management - IP dissemination & exploitation

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Gregor	Cicchetti	Paul Scherrer Institute	Villigen	gregor.cicchetti@psi.ch	structural biology for biomedical applications
BENJAMIN	Cid-Bourié	GENERAL PHARMACEUTICAL COUNCIL OF SPAIN	MADRID	benjamincid@redfarma.org	KNOWLEDGE ABOUT FUTURE PUBLIC HEALTH CARE POLICIES REGARDING TREATMENT AND DIAGNOSTICS
Sandra	Ciesek	Universitätsklinikum Frankfurt	Germany	sandra.ciesek@kgu.de	Our Institute of Medical Virology, Goethe-University Frankfurt is one of the pioneering institutes in the field of isolating and developing cell culture systems for emerging viruses. We were one of the first in the world who developed cell culture techniques enable propagation of SARS-CoV in vitro (FFM-1 and FFM-2) from patients admitted to University Hospital in Frankfurt during the outbreak in 2003. We have decades of experience with detection and characterization of antiviral drugs for coronaviruses and also other viruses (e.g. hepatitis viruses). Due to our important location close to the international airport we were also able to identify two individuals carrying new coronavirus, 2019-nCoV, during the current outbreak and expressly isolate and propagate the virus <i>in vitro</i> (Hoehl et al. NEJM 2020). Our main expertise include establishment of cell culture systems supporting full viral life cycle allowing high-throughput testing of drug banks leading to identification of compounds with

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					antiviral effect. We have already established a cell culture system for SARS-CoV-2 in our lab and started to screen antiviral compounds.
ELiana Marina	Coccia	Istituto Superiore di Sanità	Italy	eliana.coccia@iss.it	Human primary cell-based platform to evaluate the antiviral efficacy of drug candidates by studying the expression of antiviral genes.
Monika	Coronado	Forschungszentrum Juelich	Juelich	m.coronado@fz-juelich.de	binding partner studies, kinetics, lead optimization, docking and molecular dynamics
Maria Paola	Costi	University of Modena and Reggio Emilia	Modena	mariapaola.costi@unimore.it	Drug design and chemistry, enzyme extraction, purification and inhibition kinetics
Etienne	Coyaud	PRISM (University of Lille/Inserm U1192)	Lille	etienne.coyaud@inserm.fr	Proximal proteomics (BioID, TurboID), interactomics, human protein networks, mass spectrometry
Francis P.	Crawley	Good Clinical Practice Alliance – Europe (GCPA) & Strategic Initiative for Developing Capacity in Ethical Review (SIDCER)	Belgium	fpc@gcpalliance.org	Ethics Advisor and DPO on IMI & EC projects. WHO & UNAIDS & academia & industry advisor on infectious diseases & vaccines. IMI2 patient rep.
Nicolas	Creff	EFPIA	Brussels	nicolas.creff@efpia.eu	

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Maurizio	Crestani	Università degli Studi di Milano	Milano	maurizio.crestani@unimi.it	NGS platform, real time qPCR, nuclei acid detection, mass spectrometry platform for metabolomics, fuxomics and proteomics
Kim	Cryns	Janssen	Beerse	kcryns@its.jnj.com	IMI expertise
Malgorzata	Czerwec	UKRO	brussels	malgorzata.czerwec@ukro.ac.uk	Not an applicant
Demet	DAĞIDIR	SER Consultancy	Turkey	demet.dagidir@sd.com.tr	SER Consultancy offers some services like R&D and innovation management consultancy, R&D Project management, R&D incentive management, custom software programmes and training programmes to more than 350 companies from different sectors. One of our customer is university hospital. They study on diagnostic kit that is used to diagnostic of cancer.
Francesco	Dal Dosso	KU Leuven	Belgium	francesco.daldosso@kuleuven.be	IDiaLiST consortium develops and clinically validates novel point-of-care test for rapid diagnosis based on innovative bioassay concepts.
Janet	Daly	University of Nottingham	United Kingdom	janet.daly@nottingham.ac.uk	Virologist with experience in developing diagnostic tests applying technologies such as next-generation phage display
Mark	Davison	Technion Research & Development Foundaton	Israel	mark.d@trdf.technion.ac.il	Connections to Technion Researchers

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Marta	de Diego	CDTI		marta.dediego@cdti.es	
Pieter	de Koning	Leiden University Medical Center	Leiden	p.j.a.de_koning@lumc.nl	Grants advise (pre-award)
Konstantin	Denessiouk	Labmaster Ltd	Finland	konstantin.denessiouk@labmaster.fi	Labmaster Ltd. is a med-tech SME, which can bring to the project development of fast (under 15 minutes) detection diagnostics of Coronavirus infection from a blood sample.
Caroline	Desvergne	CEA/LETI/DTBS	France	caroline.desvergne@cea.fr	Diagnostics / development of fast and reliable tools.
Mara	Diaconu	Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences	Norway	mara.diaconu@ntnu.no	The Faculty of Medicine and Health Sciences (MH) is a centre for both outstanding research and education: can offer expertise in epidemiology, immunology, sepsis, clinical trials and state of the art infrastructure for research and testing.
Javier	Diez-Domingo	FISABIO-Public Health	Spain	jdiezdomingo@gmail.com	We have a hospital surveillance system set up 10 years ago, with a coverage of over 1.2 million inhabitants. Have capacity of WGS. Large experience with IMI and H2020 projects.
Alexander	Dömling	University of Groningen	The Netherlands	a.s.s.domling@rug.nl	Novel short list of potential Covid19 compounds based on approved drugs. 3CLpro: expression, screening, developing a new class of non covalent small molecules.



Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Wolfgang	Eberle	imec	Belgium	wolfgang.eberle@imec.be	a.o. fast lab analytics/diagnostic chips as platform for diagnostic assays or for pre-clinical R&D. Manufacturing capability.
Sol	Efroni	Bar Ilan University	Israel	sol.efroni@biu.ac.il	Computational Immunology. Immunological repertoire. Machine learning over high throughput biological data
Riin	Ehin	Bravo Healthcare	Estonia	riin.ehin@bravohealthcare.ee	Concept of vaccine development that is effective, safe, fast and would enable cheap production, partners from non-EU countries
Rolando	Eisen	Imanu Immunotherapy, Inc.	Israel	rolando@ughpharma.com	Expertise and a proprietary molecule which reverts the immune system to its pre-suppressed state.
Sena	Erdil	atabay	Turkey	senaerdil@yahoo.com	cov
Wolfgang	Fecke	EU-OPENSREEN ERIC	Germany	wolfgang.fecke@eu-openscreen.eu	With our library of 100.000 commercial and a number of academically sourced compounds, our partners can identify hits and develop them into drug candidates.
Sandra	Fernández	Germans Trias i Pujol Research Institute	Spain	sfernandez@igtp.cat	Project Management
Dmitri	Filippov	Leiden University	The Netherlands	filippov@chem.leidenuniv.nl	Cleavage of ADP-ribose from proteins is essential for coronavirus. I can design mimetics of ADP-ribose to develop antiviral drugs.
Bernhard	Fischer	APEPTICO	Austria	b.fischer@apeptico.com	Clinical stage therapeutic molecule for immediate treatment of patients infected with coronavirus

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Florian	Fröwis	ID Quantique	Switzerland	florian.froewis@idquantique.com	ID Quantique offers expertise in single-photon detection to significantly improve PCR performance (evaluation time, costs, ...).
Marcus	Furch	Rodos Biotarget GmbH	Germany	M.furch@biotargeting.eu	We provide a preclinical stage nanomedicine comprising a nanocarrier that specifically addresses cell receptors on antigen presenting cells (APC) loaded with a broad spectrum antiviral. Many different, including deadly, viruses subvert the function of those cell receptors to escape antiviral immunity and promote infection. They function as an attachment receptor for viral envelope glycoproteins of HCV, DENV, CMV, IAV, EBOV, MARV, SARS Cov, MERS Cov and thus very likely of the new strain causing COVID-19, too, and facilitate transmission to susceptible cells within an infected species.
Eithan	Galun	Hadassah Hebrew University Hospital	Israel	eithang@hadassah.org.il	A novel new diagnostic unbiased platform based on peptidomics
Federico	Garcia	HU San cecilio	Spain	fegarcia@ugr.es	Diagnostics, POC testing, DNA sequencing
Cody	Geary	Aarhus University	Denmark	geary@inano.au.dk	RNA nanostructure expert, in vitro selection, RNA structural modeling, RNA sequence design algorithm, RNA structure design
Aharon	Gedanken	Bar-Ilan University	Israel	gedanken@mail.biu.ac.il	I would like to suggest building a new factory for making face masks that will inhibit the attack of the corona virus as well as

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Nick	Geukens	KU Leuven	Belgium	nick.geukens@kuleuven.be	PharmAbs: Protective human monoclonal antibody screening platform; DNA-platform for in vivo delivery of protective antibodies.
Carlo	Giaquinto	Penta Foundation	Italy	carlo.giaquinto@unipd.it	A bridging point to the largest global independent scientific network dedicated to paediatric research. Know-how as C4C leader.
Thomas	Gillespie	PHE	United Kingdom	thomas.gillespie@phe.gov.uk	Business development expertise.
Daniel	Gillet	CEA	France	daniel.gillet@cea.fr	Molecules
Federico	Giorgi	University of Bologna, Department of Pharmacy and Biotechnology	Italy	federico.giorgi@unibo.it	loinformatics, Genomics and Transcriptomics. We published the first large genomic comparison of SARS-CoV-2 on Feb-6-2020 (PMID 32027036).
Tania	Godoy	Interuniversity Research Institute of Molecular Recognition and Technological Development from Polytechnic University of Valencia (IDM)	Spain	tago@upv.es	The development of an optical and selective probe for rapid and in situ detection of coronavirus infections.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Andrew	Goldsborough	RNAssist Ltd.	United Kingdom	A.Goldsborough@RNAssist.com	Expertise in RNA/DNA virus stabilisation & inactivation for safely transporting clinical samples to diagnostic testing labs.
Marta	GOMEZ QUINTANILLA	CDTI	Spain	marta.gomez@cdti.es	I won't be participating in the project.
Natalie	Gordon	Bar Ilan University	Israel	natalia.gordon@biu.ac.il	diagnostics to rapidly and reliably identify people infected with COVID-19
Ulrich	Gosewinkel	Aarhus University	Denmark	ulrich.gosewinkel@envs.au.dk	Development of devices that collect biological particles from air into an aqueous liquid, suitable for downstream analysis of the microorganism of interest.
Paolo	Greco	University of Naples	Italy	paolo.grieco@unina.it	Own Experience in Peptide Chemistry in the discovery of antimicrobial and antiviral agents.
Philip	Gribbon	Fraunhofer IME	Germany	Philip.Gribbon@ime.fraunhofer.de	Deep expertise in screening and compound repurposing. Library > 5400 known drugs and bioactives. Informatics workflows in place.
Harald	Gröger	Bielefeld University	Germany	harald.groege@uni-bielefeld.de	Synthesis of chiral small molecule libraries with unique structural motifs for drug testing utilizing bio- and chemocatalysis as key steps.
Karl	Gruber	University of Graz	Austria		The fastcure.net consortium aims to repurpose drugs against SARS-CoV-2. 17 partners cover expertise in-silico and experimental drug screening and evaluation.
Christian	Gruber	Innophore	Austria	christian.gruber@innophore.com	The fastcure.net consortium aims to repurpose drugs against SARS-CoV-2. 17 partners cover expertise in-silico and experimental drug screening and evaluation.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Verena	Grützner	Fraunhofer Institute for Microengineering and Microsystems IMM	Germany	verena.gruetzner@imm.fraunhofer.de	A microfluidic lab-on-a-chip platform for molecular POC diagnostics and fast detection of virological infection status.
Jurgen	Haas	University of Edinburgh	United Kingdom	juergen.haas@ed.ac.uk	Identification of SARS-CoV2 inhibitors and potential anti-viral drugs by genome-wide siRNA and CRISPR screens; virological expertise The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336.
Hossam	Haick	Technion - Israel Institute of Technology	Israel	hhossam@technion.ac.il	Developing and validation of non-invasive wearable devices for detection of infectious diseases via breath and skin.
James	Hall	Athera Biotechnologies AB	Sweden	j.hall@athera.se	oxPL drives ARDS in COVID-19 (Imai et al 2008). Athera's oxPL mAB is in PhII testing in STEMI patients, and will be tested in COVID-19 patients.
Tomer	Hertz	Ben-Gurion University	Israel	thertz@bgu.ac.il	Antibody profiling using antigen microarrays. Interested to partner with groups seeking to develop serological tests for COVID-19.
Peter	Hinterdorfer	Johannes Kepler University Linz	Austria	peter.hinterdorfer@jku.at	Decipher interaction forces and energies of viruses or viral proteins with drugs, antibodies, and cells at the single-molecule level using force microscopy.
Dilem	Hizlan	Sabanci University	Turkey	dilem.hizlan@sabanciuniv.edu	Consortium building

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Kourosh	Honarmand Ebrahimi	University of Oxford	United Kingdom	kourosh.honarmandebrahimi@chem.ox.ac.uk	Multidisciplinary research skills at area of enzymology, virology, innate immune system, discovery of new antiviral nucleotides
Shie-Liang	Hsieh	Genomics Research Center, Academia Sinica	Taiwan	slhsieh@gate.sinica.edu.tw	Serological testing, Pathogenesis of COVID-induced cytokine storm
Sasha	Hugentobler	Euresearch	Switzerland	sasha.hugentobler@euresearch.ch	I can assist the proposal preparation as Health National Contact Person to Health Horizon 2020
Oyvind	Ihlen	U of Oslo	Norway	oyvind.ihlen@media.uio.no	Knowledge of strategic communication on risk and crisis; channel use and content strategies
Isabelle	Imbert	Aix Marseille University	France	isabelle.imbert@univ-amu.fr	We have reconstituted in vitro the SARS-CoV replicative machine
Fatih	Inci	Bilkent University - UNAM	Turkey	finci@bilkent.edu.tr	point of care diagnostics, microfluidics, infectious diseases, biosensors
Penelle	Jacques	CNRS	France	penelle@icmpe.cnrs.fr	Coordination of a network on peptide- and peptidomimetic-based drugs as antiviral agents, either as single drugs or in combination therapies.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Alba	Jene Sanz	BSC	Spain	alba.jene@bsc.es	HPC, molecular dynamics simulations of the viral proteins and the ultrafast virtual screening of libraries
Gisli	Jenkins	University of Nottingham	United Kingdom	gisli.jenkins@nottingham.ac.uk	Alveolar epithelial expertise, ACE2 measurement expertise, acute lung injury expertise, cell, molecular and in vivo modeling expertise.
Shisong	Jiang	University of Oxford	United Kingdom	Shisong.jiang@oncology.ox.ac.uk	Peptide therapeutics.
Samuel	Jones	University of Manchester	United Kingdom	samuel.jones-4@manchester.ac.uk	Have developed broad-spectrum destroy on contact antivirals that are non-toxic and looking to explore their uses.
Rita	Juneja	Pharmaceutical Research & Manufacturers Association (PReMA)	Thailand	rita@prema.or.th	The Pharmaceutical Research & Manufacturers Association (PReMA) is a non-profit organization representing research based pharmaceutical companies. Together with our members, PReMA brings the industry and broader health community together to foster research and innovation ecosystem. PReMA works collaboratively with other health players both locally and internationally to provide collective solutions in promoting health innovation and enhancing the quality of patient's lives. With this reason, we are very interested in joining IMI platform and have been attended several webinars to gain insights on how PReMA and Thai researchers can contribute in accelerating the medicine development process and bring out new scientific insights to be shared with

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					public. PReMA would like to explore the potential for collaboration and would kindly like to be in the IMI participants list for networking on COVID-19 and other relevant topics.
David	Kat	Bridgeheads	Israel	david@bridgeheads.nl	Intends to develop a viable Covid-19 test with modified Spectral Light Detector & Amplification Circuit in the molecular structure of fluids.
Sebastian	Kersting	Fraunhofer IZI-BB (Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses IZI-BB)	Germany	sebastian.kersting@izi-bb.fraunhofer.de	Development of rapid POCTs (LFAs, portable nucleic acid amplification, etc.). Establishing/ validation of isothermal NAATs. Sample collection and preparation.
ATA UL RAZZAQ	KHAN	University of Oslo	Norway	hafizata330@gmail.com	Have experience in pharmaceuticals, epidemiology and infectious disease modelling.
Peter	Kidney	Hibergene Diagnostics Ltd	Ireland	Peter.kidney@hibergene.com	HiberGene Diagnostics develops and manufactures rapid Mdx tests for infectious diseases, having CE marked 10 products to date including Flu and RSV. We have designed a rapid Mdx test for COVID-19, specifically required by the call (that provides a positive result in circa 20-30 minutes) and aim to ship first prototype test to our China-based distributor in March for laboratory evaluation with local samples. We have selected a highly experienced specialist



Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					instrument developer to transition our proven diagnostic chemistry into a simple sample-to-result Mdx diagnostic cartridge and low-cost instrument which is designed to meet USA CLIA waiver specifications and suitable for use at Point of Care, including health clinics and physician offices. The proposed diagnostic assay and system will facilitate rapid diagnosis and management of patients suspected of COVID-19 infection.
Dov	Kivel	Innolabs Ltd	Israel	dovkivel101@gmail.com	An Immuno-modulator providing organism protection of organism against viral diseases has been extensively tested on animals and particular broiler - completely suppresses chicken mortality (except on birthday) Functionality will be enhanced /improved for use with Coronavirus. We will also develop specific tools for various delivery scenarios.
Omry	Koren			omry.koren@biu.ac.il	Microbiome research
Sarah	Kotovotz	LN Pharma	Israel	Sarah.sealaria@gmail.com	
Jeroen	Lammertyn	KU Leuven	Belgium	jeroen.lammertyn@kuleuven.be	Biosensors group develops biosensing platforms based on immuno & DNA ultrasensitive multiplexing assay for infectious diseases.
Loulieta	Lazarou	Information Technologies Institute (ITI)	Greece	iouliettalaz@iti.gr	Remote monitoring technologies, IoT for large-scale pilots, image analysis, semantic clinical and domain knowledge sensor fusion, smart-home.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Dorota	Lesiak	Institute of Biotechnology and Molecular Medicine (IBMM)	Poland	Dorota.lesiak@ibmm.org.pl	We would like to develop tools allowing for on-site screening of clinical samples in order to detect patients infected with 2019-nCoV.
Maryse	Letiembre	Institute for Research in Biomedicine (IRB)	Switzerland	maryse.letiembre@irb.usi.ch	isolation and characterization of human monoclonal antibodies; in vivo imaging; computational visualization of interactions
Tamás	Letoha	Pharmacoidea Ltd.	Hungary	tamas.letoha@pharmacoidea.eu	Viral entry studies, virus-receptor studies, viral endocytosis, retrograde transport, glycan assays, management, dissemination
Nouara	Lhocine	Institut IMAGINE	France	nouara.lhocine@institutimagine.org	Cohorts, clinical data, expertise in genetics, platforms
Anastasia	Liapis	GNA Biosolutions GmbH	Germany	liapis@gna-bio.com	Award-winning technology developer of portable instruments and ultrafast tests for molecular diagnostics. IMI consortium lead on Ebola detection (FILODIAG).
Jung-Hsin	Lin	Academia Sinica	Taiwan	jhlin@gate.sinica.edu.tw	determination of target protein structures, discovery of small molecule compounds
Vanessa	Llobet	IGTP	Spain	vllobet@igtp.cat	Expertise and infrastructure

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Maritta	Löytömäki	University of Turku	Finland	makrpy@utu.fi	n/a
Arthur	Machlenkin	Pantheon Biosciences	Israel	arthurm@pantheonbio.com	Pantheon has established powerful platform for developing potent antiviral therapeutics against various human viruses including COVID-19.
Ricardo	Madrid	BioAssays SL	Spain	rmadrid@bioassays.es	Development of a molecular IVD using DNA-nanoprobes for COVID-19 detection from saliva and blood samples. Easy to handle for its use at POCs in <45'.
Diletta	Magini	Sclavo Vaccines Association	Italy	magini@fondazionesclavo.org	Management, Dissemination and Impact Assessment
Stuart	Malcolm	LSHTM	United Kingdom	stuart.malcolm@lshtm.ac.uk	Research experience, project management skills
Anita	Marinelli	University of Bologna	Italy	anita.marinelli3@unibo.it	As part of the UNIBO Research and Grant Office, I can put prospective applicants in contact with our researchers (matchmaking)
Stefano	Marini	Dati & Ricerca consultant for E-Pharma	Italy	sfm.marini@gmail.com	Strategic plan for product development, including preclinical toxicology, pharmacokinetics and clinical trials
Donata	Medaglini	University of Siena/Sclavo Vaccines Association	Italy	medaglini@sclavo.org	Microbiology, analysis of host-pathogen immune responses, animal studies, management and coordination
Ainara	Mira-Iglesias	FISABIO-Public Health	Spain	mira_ain@gva.es	Researcher in the Vaccine Research Department of FISABIO-Public Health and coordinator of a surveillance hospital network for the study of respiratory infections.
Emanuele	Montomoli	VisMederi srl	Italy	montomoli@vismederi.com	laboratory support

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Thiago	Moreno L. Souza	Fiocruz	Brazil	tmoreno@cdts.fiocruz.br	Pre-clinical antiviral research including flavonoids from the brazilian flora.
Liana	Naim	LN Pharma	Israel	ln@lnpharma.com	
Olivier	Namy	CNRS	France	olivier.namy@i2bc.paris-saclay.fr	an innovative and specific target to inhibit coronavirus replication. Our proposal will focus on HTS for approved drugs.
Rahul	Narang	Marker Health	Switzerland	rnarang@markerhealth.co	Marker's universal adsorption cartridge reduces severity, morbidity and mortality associated with Covid-19 pneumonia complications.
Veronica	Negro	BforCure	France	veronica.negro@bforcure.com	We are able to detect COVID-19 by qPCR using the set of primers and probe N1 of the CDC in 11 minutes (200 copies of nucleocapsid cDNA cloned in a plasmid).
Lianet	Noda Garcia	Pantheon Biosciences	Israel	lianetng@pantheonbio.com	We develop new nucleoside analogues as antivirals.
Hanna	Nohynek	THL National Institute for Health and Welfare	Finland	hanna.nohynek@thl.fi	Vaccinology, immunology, research ethics, clinical trials, public health decision making
Shai	Novik	Enlivex Therapeutics, Ltd	Israel	shai@enlivexpharm.com	Clinical-stage therapy for the treatment of organ failure associated with sepsis, which has similar pathophysiology of organ failure of coronavirus patients in the ICU
Guillaume	Noyel	International Prevention Research Institute - IPRI	France	guillaume.noyel@i-pri.org	Medical image analysis for clinical diagnosis. New mathematical methods and algorithms to analyse images acquired in real conditions (contrast variations, etc.).

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Lars	Oetjen	Nisooh Inc.	United States	<a href="mailto:lars.oetjen@nisooh11.com">lars.oetjen@nisooh11.com</a>	Support of Associated Partner (BMGF) to the program
Adar L	Oni Grinberg	TAU	Israel	<a href="mailto:adarlea@tauex.tau.ac.il">adarlea@tauex.tau.ac.il</a>	Corona Virus Researchers
Tal	Or	ATLASense Biomed Ltd.	Israel	<a href="mailto:tal.or@atlasensebiomed.com">tal.or@atlasensebiomed.com</a>	A predictive analytics project to early detection of suspicious for COVID-19, based on our comprehensive, continuous remote monitoring platform.
Lourdes	Palacios	Progenika Biopharma	Spain	<a href="mailto:lourdes.palacios@progenika.grifols.com">lourdes.palacios@progenika.grifols.com</a>	We develop molecular reagents for diagnosis. I am expert in NGS (Illumina and ONT), including sequencing of viral genomes
Elena	Pariani	University of Milan	Italy	<a href="mailto:elena.pariani@unimi.it">elena.pariani@unimi.it</a>	Expertise in virology
Paresh	Parmar	Imperial College London	United Kingdom	<a href="mailto:paresh.parmar@imperial.ac.uk">paresh.parmar@imperial.ac.uk</a>	Rapid and ultrasensitive point of care diagnostic test for Covid-19. We have relevant expertise (demonstrated with HIV) for test
Johannes	Peham	AIT Austrian Institute of Technology	Austria	<a href="mailto:Johannes.peham@ait.ac.at">Johannes.peham@ait.ac.at</a>	Point of Care Devices, Rapid Testing, Assay Development, Sample Preparation, System Integration, Production Transfer.
CECILE	PELTEKIAN	Institut Pasteur	France	<a href="mailto:cecile.pelteikian@pasteur.fr">cecile.pelteikian@pasteur.fr</a>	Our teams have expertise in Virology, Immunologie, drug screening and are at the frontline to advance knowledge on COVID 19
Susi	Petri	Institute of Biomedicine, University of Turku	Finland	<a href="mailto:pesusi@utu.fi">pesusi@utu.fi</a>	BSL3, virus sample access, antigen design and production, expertise in POC development, human antibody libraries for therapy development.
Paula	Petrone	Phenobyte	Spain	<a href="mailto:paula.petrone@phenobytelife.com">paula.petrone@phenobytelife.com</a>	Data science, data engineering and bioinformatics expertise focused in the life science, in particular drug discovery sector.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					Expertise in virus biological pathways and bioinformatics.
Silvia	Picciolini	Fondazione Don Gnocchi	Italy	spicciolini@dongnocchi.it	Biophotonics for fast diagnostic analysis
claudio	pisano	Special Product Line SPL	Italy	c.pisano@specialspa.it	production in tobacco of COVID-19 proteins
Katrina	Pollock	Imperial College London	United Kingdom	k.pollock@imperial.ac.uk	Senior Clinical Research Fellow at Imperial College London; expertise in immunology and clinical management of severe pneumonia
Prajwal	Prajwal	University of Zurich	Switzerland	prajwal@clemmedi.com	Science and technology
Natalya	Prilipko	University of Haifa	Israel	natalyap@univ.haifa.ac.il	Trying to understand what experts from our institution will best suit this opportunity.
Stefan	Prof. Dr. Pöhlmann	German Primate Center, Infection Biology Unit	Germany	spoehlmann@dpz.eu	Tools for analysis of SARS-CoV-2 host cell interactions, potential therapeutics, non-human primate model
Krzysztof	Pyrz	Jagiellonian University in Krakow	Poland	k.a.pyrc@uj.edu.pl	HAE cultures and organoids + genetically modified HAEs, antivirals, surrogate systems (pseudoviruses, VLPs).
Daniel	Quesada-González	Paperdrop Diagnostics	Spain	dquesada@paperdropdx.com	Paperdrop Dx develops rapid (less than 20 min) diagnostic tests based on paper using almost any type of bioreceptor (e.g. antibodies).
Marco	Radi	University of Parma	Italy	marco.radi@unipr.it	Design & Synthesis of Antivirals, repurposing of in house antivirals, broad-spectrum antivirals, non-nucleosides & nucleosides
Shirly	Rakier	Technion	Israel	shirlyr@trdf.technion.ac.il	I will search for experts within our campus in line with the project needs

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Doris	Rakoczy	AIT Austrian Institute of Technology GmbH	Austria	doris.rakoczy@ait.ac.at	molecular diagnostics, biomarker research, assay development, bioinformatics, biosensors & system integration, biolog. barriers
Raj	Reddy	Canary Health Technologies	USA	raj@canaryhealthtech.com	Low cost, real-time (under 5 minutes), rapid breath portable test to distinguish COVID-19 patients from healthy. Canary Health Technologies ( www.canaryhealthtech.com) Airostotle™ platform can be tuned through a short development process to start testing in COVID-19 infected patients with selected infectious disease partners who are already on the ground in a case controlled study to develop a real-time breath testing platform for rapid deployment in light of the current global emergency.
Félix	Rey	Institut Pasteur	France	felix.rey@pasteur.fr	Approach that is both diagnostics and therapeutics including the use of antibodies and small compounds.
Wolfram	Rieneck	Medical University Innsbruck	Austria	wolfram.rieneck@i-med.ac.at	Institute of virology
Silvia	Riva	Department of Psychology and Pedagogic Science. Faculty of Sport, Health and Applied	United Kingdom	silvia.riva@stmarys.ac.uk	Technical skills: proficiency/expertise with the analysis of risk perception in health. Transferable skills: identification of new strategies of health communication that can be used in Public Sector Nationally and Cross-Nationally. High experience with EU project

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
		Science, St Mary's University			
Davide	Robbiani	The Rockefeller University / Institute for Research in Biomedicine, USI	United States	drobbiani@rockefeller.edu	human antibody discovery and characterization, global network for the acquisition of human samples (including Asia), ADE
Sylwia	Rodziejewicz-Motowidło	University of Gdańsk	Poland	s.rodziejewicz-motowidlo@ug.edu.pl	I would like to participate in the consortium as a partner preparing the project for the IMI competition: "Development of therapeutics and diagnostics combatting coronavirus infections". My participation in the consortium would be to provide compounds synthesized in the laboratory by organic synthesis way with antiviral/anticoronaviral activity. These compounds have no known mechanism of action or molecular target.
Francesca	Rossi	Istituto di Fisica Applicata Consiglio Nazionale delle Ricerche	Italy	f.rossi@ifac.cnr.it	We are developing a rapid (few minutes) system for identification of DNA based on nanotechnology (plasmon resonant sensors) and photonics-based devices. So we are interested to the topic "development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies" of the call.



Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Christian	Rötz	CrystalsFirst GmbH	Germany	christian.roetz@crystalsfirst.com	fragment-based drug discovery, high throughput primary screening using protein crystals, proprietary soaking technology
Valérie	Roux-Jallet	CEA-LETI	France	valerie.roux@cea.fr	CEA-LETI can bring its expertise in microfluidic POC device to rapidly develop a new ultrafast diagnostic test for the 2019-nCoV.
Katharina	Rox	Helmholtz Centre for Infection Research (HZI)	Germany	katharina.rox@helmholtz-hzi.de	Pharmacology, pharmacokinetics, ADME, formulation development for small molecules
Francisco	Rubio	Glaxosmithkline	Spain	francisco-javier.p.rubio-pomar@gsk.com	Expertise in Proposal Preparation and Project Management.
Päivi	Saavalainen	University of Helsinki	Finland	paivi.saavalainen@helsinki.fi	Rapid and sensitive 2019-nCoV RT-PCR diagnostic platform which we are developing for point-of-care use
Xavier	Saelens	Ghent University and VIB	Belgium	xavier.saelens@vib-ugent.be	COVID-19 targeting single domain antibodies
Chen	Sagiv	DeePathology Ltd.	Israel	chen@deepathology.ai	AI tools to analyze microscopic images relying on DeePathology STUDIO, a Do It Yourself platform that serves as AI solutions creator for digital pathology.
kumar singh	saikatendu	Takeda Pharmaceuticals	United States	kumar.saikatendu@takeda.com	prior extensive experience on coronavirus program
Marina	Sala	University of Salerno	Italy	msala@unisa.it	Development and lead optimization of peptide or small molecules with already tested antiviral activity that could be study as potential therapeutic against the current COVID-19.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Sancha	Salgueiro	chart Biotechnology	Denmark	sancha@chartbio.eu	mAb and viral protein expression capability, virus-like-particles
Gunnar	Sandberg	Vinnova	Sweden	gunnar.sandberg@vinnova.se	SRG
Aviram	Sariel	SURI Technologies	Israel	aviram.sariel@suri-technologies.com	SURI developed the science/technology of harvesting immune ab repertoire from patients, identifying relevant tumor-specific abs, produce and use them for conjugate drug delivery. The process is highly patient specific. We think it is also suited as a first line of defense against viral and bacterial epidemic. Would be happy to learn how we can advance these concepts.
Borbala	Schenk	Dr. Borbala Schenk Consultancy	Hungary	borbala.schenk@researchmanagement.hu	Assistance in consortium-building: connections with Hungarian institutions, stakeholder organizations, SMEs with competences and expertise relevant to the call.
Claudia	Scotti	University of Pavia	Italy	claudia.scotti@unipv.it	We have the expertise to develop anti-viral, anti-receptor antibodies and engineered forms of pulmonary surfactant proteins, including structural work.
Mario	Sechi	University of Sassari	Italy	mario.sechi@uniss.it	Expertise in Targeted delivery approaches
Magnus	Seierstad	University of Oslo	Norway	magnseie@uio.no	Research in the field of medicine
Steven	Sepúlveda	Mesa Biotech, Inc.	USA	ssepulveda@mesabiotech.com	

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Romano	Silvestri	University of Roma	Italy	romano.silvestri@uniroma1.it	My medicinal chemistry research group includes both synthetic and computational units. We have a large know-how in the design and synthesis of antiviral agents, including HIV, DENV and ZIKA. Moreover, we have a compound collection of >6000 compounds available for screening as powder and for virtual screening as .sdf format.
Dan	Smith	Prism Ideas Ltd	United Kingdom	Dan.Smith@prismideas.com	Rapid drafting of documents needed for evidence generation & evaluation; communication & result dissemination. Expertise from prior virology & diagnostics work.
Claudio	Soares	ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa	Portugal	claudio@itqb.unl.pt	We are a computational biology lab aiming to apply our vast experience with viral fusion proteins (VFPs)
Tamas	Sohajda	Cyclolab Cyclodextrin Research and Development Ltd	Hungary	sohajda@cyclolab.hu	Cyclolab is specialized in cyclodextrins that can help prevention of virus spreading as well as used as antiviral NCEs (PoC demonstrated).
Montserrat	Sole	IBB	Spain	montserrat.sole.castellvi@uab.cat	Diagnostics using a lateral flow system or any participation related to nanoparticles/genomic analysis.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Francesca	Spyrakis	University of Turin, Dep. of Drug Science and Technology	Italy	francesca.spyrakis@unito.it	Strong expertise in computational chemistry
Carl	Steinbeisser	collaborate.eu	Germany	carl@collaborate.eu	good track record in project management and proposal writing
Thomas	Steiner	MChE/F4-Pharma	Austria	Thomas.steiner@mche.at	FX 06 , a drug expected to have a beneficial effect on the pathophysiological host response to the infection
Sorin	Stircu	E*HealthLine	Belgium	sorin.stircu@ehleahline.com	Digital Biomarker-Digital Therapeutics Platform to early diagnose, surveillance, to track, monitor individuals suspect of acquiring COVID-19.
Daniela	Strodthoff	Karolinska Institutet	Sweden	daniela.strodthoff@ki.se	Central support from Grants Office
Ulrich	Strych	Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine	United States	strych@bcm.edu	Developed vaccines for SARS and MERS; cGMP-produced SARS-CoV RBD DS
Wei-Zen	Sun	National Taiwan University Hospital	Taiwan	wzsun@ntu.edu.tw	Harnessing wearable device network to improve real-time surveillance among quarantined population
Erno	Sundberg	Abacus Diagnostica	Finland	erno.sundberg@abacusdiagnostica.com	Abacus' is having strong expertise of rapid development and having affordable CE IVD approved solution for decentralized PCR diagnostics.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Petri	Susi	University of Turku	Finland	pesusi@utu.fi	BSL3 lab (brand-new), expertise antibodies and rapid diagnostics development, human scFv/Fab libraries for therapy development
Michael	Szardenings	Fraunhofer Institute for Cell Therapy and Immunology	Germany	Michael.szardenings@izi.fraunhofer.de	Rapid mapping 2D&3D antibody epitopes at amino acid resolution directly from serum, experience with allergies, infectious dis., vaccines.
John	T.-A. Hsu	National Health Research Institutes	Taiwan	tsuanhsu@nhri.org.tw	We will develop a 3CL protease inhibitor for coronaviruses. Since 2003, we have accumulated extensive experiences for discovery of 3C-like protease of SARS-CoV.
davide	taffurelli	E PHARMA TRENTO S.p.A	Italy	d.taffurelli@e-pharma.com	PHARMACEUTICAL DEVELOPMENT
Farzin	Takyar	National Institute for Medical Research Development (NIMAD)	Iran	ftakyar@gmail.com	Some researchers in my network have access to a significant number of patients suspected of/having COVID-19. CT scans and potential of obtaining blood, urine, and other samples is available. Basic molecular biology techniques are also available.
Thavirap	Tantiwongse	Pharmaceutical Research & Manufacturers Association (PReMA)	Thailand	thavirap@prema.or.th	The Pharmaceutical Research & Manufacturers Association (PReMA) is a non-profit organization representing research based pharmaceutical companies. Together with our members, PReMA brings the industry and broader health community together to foster research and innovation ecosystem. PReMA works collaboratively with other health players both locally and internationally to provide collective

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					solutions in promoting health innovation and enhancing the quality of patient's lives. With this reason, we are very interested in joining IMI platform and have been attended several webinars to gain insights on how PReMA and Thai researchers can contribute in accelerating the medicine development process and bring out new scientific insights to be shared with public. PReMA would like to explore the potential for collaboration and would kindly like to be in the IMI participants list for networking on COVID-19 and other relevant topics.
Donatella	Taramelli	Università degli Studi di Milano	Italy	donatella.taramelli@unimi.it	Small library of compounds available for screening: quinolines derivatives and endoperoxides, one with non formal preclinical testing done.
Paola	Tarroni	Axxam SpA	Italy	paola.tarroni.pt@axxam.com	Implementation of HTS assays - Hit identification from Axxam library (325k druglike cpds for Drug Discovery) & from others' libraries - Hit/Lead triage.
Dogan	Taskent	atabay	Turkey	dogan.taskent@atabay.com	cov
Victoria	Taylor	Arcis Biotechnology	United Kingdom	Victoria.taylor@arcisbio.com	Arcis Biotechnology have developed a rapid DNA and RNA extraction kit that is ideally positioned for use in point-of-care.
Daniela	Teriaca	IPSEN SPA	Italy	daniela.teriaca@ipsen.com	REGULATORY AFFAIRS
Yaakov	Tischler	Bar-Ilan University	Israel	yrt@biu.ac.il	Non-invasive lased based diagnosis using compact high-throughput Raman Spectroscopy device

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Eran	Toledo	Sanara Ventures	Israel	eran@sanaraventures.com	Project: point of care, accurate, low cost, 30 sec detection of SARS-CoV-2 using a highly sensitive optical detection mechanism without the need for amplification.
Giovanni	Tosi	Department of Life Sciences, UNIVERSITY OF MODENA AND REGGIO EMILIA	Italy	gtosi@unimore.it	Expertises to be exploited in the project is on drug delivery systems and innovative pharmaceutical technologies which are available and in the “ skills of Nanotech Lab, in order to better produce tailored drug delivery systems for therapeutic agents in the local site of action. Drug delivery systems could be designed, prepared and exploited to ameliorate rate of success, useful in drug protection and on-site drug release in particular in this pathology in which it is pivotal to bring the higher amount of drug where it is needed, as the issues in delivering antiviral drugs in correct site of activity are already known and could hamper the final success of therapies.
Andrea	Trabocchi	Università degli Studi di Firenze	Italy	andrea.trabocchi@unifi.it	Peptidomimetic NCE, in house inhibitors of SAP2 and HIV aspartic proteases; small library ready to test, easy synthesis.
Ahmet	Turkdemir	Ankara 112 Prehospital Emergency Health Service	Turkey	eturkdemir@yahoo.com	I can share my experiences in pre-hospital emergency health services, and as an Emergency and Disaster Epidemiology Specialist,

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Lars	Ullerich	GNA Biosolutions GmbH	Germany	ullerich@gna-bio.com	Portable molecular testing device and assay (based on WHO suggestion) for Sars-CoV-19 for point-of-need testing in minutes.
Beatrice	Vallone	Università di Roma	Italy	beatrice.vallone@uniroma1.it	Protein structure determination for rational drug design, repositioning of drugs and library screening by crystallography. Single particle CryoEM for the structure of large macromolecular assemblies such as viral receptors-target complexes.
Luca	Varani	Institute for Research in Biomedicine, Università della Svizzera italiana	Switzerland	luca.varani@irb.usi.ch	Characterization, design, production of Abs (also bispecific) and antigens. High impact (eg Cell) on supercomputing of Ab/virus (Zika, MERS).
Teresa	Vazquez Lopez	BPI (German Pharmaceutical Industry Association)	Belgium	tlopez@bpi.de	Representation of the German Industry
Christophe	Verbruggen	Johnson&Johnson	United States	cverbrug@its.jnj.com	N.a.
Ernst	Verschoor	Biomedical Primate Research Centre (BPRC)	Netherlands	verschoor@bprc.nl	Nonhuman primates, BSL3+ facility, PK and antiviral efficacy testing of antivirals in macaques and marmosets
Babs	Verstrepen	Biomedical Primate Research Centre (BPRC)	The Netherlands	verstrepen@bprc.nl	BPRC is a non profit organization specialized in modeling human (infectious) diseases in nonhuman primates (macaques and common marmosets) to study pathology, immunological



Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					parameters and proof-of-concept studies for therapeutic and prophylactic intervention strategies.
Rotem	Vishinkin	Technion - Israel Institute of Technology	Israel	rvishinkin@technion.ac.il	Developing and validation of non-invasive wearable devices for detection of infectious diseases via breath and skin.
Monika	Vrajova	Technology Centre of the CAS	Czech Republic	vrajova@tc.cz	As NCP for health I should help scientists with proposal preparing
Estelle	Waise			estelle.waise@biu.ac.il	ELO
Katrin	Weinhandl	acib GmbH	Austria	katrin.weinhandl@acib.at	Broad network in the field of industrial biotechnology, dissemination/communication and exploitation skills
David	Wilson	Avacta Life Sciences Ltd	United Kingdom	david.wilson@avacta.com	Avacta Life Sciences is interested in joint development of a rapid SARS-COV-2 screening test that can be deployed in near patient testing settings, such as primary care or community settings, utilising Avacta's proprietary Affimer® technology to rapidly develop robust, highly specific protein affinity binders to SARS-COV-2 antigens on a lateral flow platform.
Anders	Wolff	Department of Biotechnology and Biomedicine Technical, University of Denmark	Denmark	awol@dtu.dk	We will provide one "front line" and two "second line" diagnostic tools for COVID-19. The "front line" diagnostics can be performed as a rapid (less than 1 minutes), simple, point of care test (POC) in the field by a minimally trained person (e.g. at hospitals or clinics, at point of entry, in a plane, on a cruise ship, in an

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					ambulance, on a parking lot, in a home quarantine setting etc.). The “second line” diagnostics require minimum (portable) equipment and can be performed by briefly trained personnel in hospitals, primary health care units or in mobile laboratories. These solutions will be available in month 4 and EUA applications will be submitted by month 7. These POCs with lab and field evaluations will allow for fast detection and surveillance of the epidemic and greatly improve the diagnosis and clinical management of patients infected with COVID-19. We are looking for partners that can contribute to address the therapeutic aspects.
Petra	Wuelfroth	accella advisors GmbH	Switzerland	petra.wuelfroth@accella-advisors.com	coordination of complex cooperations between SMEs, research institutions and government programs. experience in drug development
Noam	Zeichner	LN Pharma	Israel	noam.sealaria@gmail.com	
Xunli	Zhang	University of Southampton	United Kingdom	XL.Zhang@soton.ac.uk	Microfluidic/Lab-on-a-Chip technologies for clinically-relevant applications, e.g. tuberculosis pandemic, and AMR rapid diagnostics.
Rami	Zigdon	Todos Medical	Israel	rami@todosmedical.com	A screening test for the Corona Virus
Giampaolo	Zuccheri	Alma Mater Studiorum Università di Bologna, Department of	Italy	giampaolo.zuccheri@unibo.it	I could offer my expertise on: Design, preparation and characterization of nucleic acids nanostructures that could reduce the intracellular RNA content. Development of biosensors for the detection of nucleic acids.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
		Pharmacy and Biotechnology			
Álvaro	Aceña	IIS Fundación Jiménez Díaz	Spain	aacena@fjd.es	<p>I would bring to the project a randomized study with statins in patients with coronavirus infection or at risk of infection. The beneficial effects of statins are not only cholesterol reduction , but that they have immunomodulatory and anti-inflammatory properties. Furthermore, cholesterol allows invasion by pathogens by acting as a docking site for the internalization of virus.</p> <p>We have a preeliminary data (under review in this moment) in which statin use was associated with mortality benefit in patients with a Respiratory Virus Infection confirmed by laboratory tests in our center. So we think statins could provide a useful option for the treatment of Virus Infections in the future.</p>
David	Alexander	Ontera	USA	david.alexander@ontera.bio	Ontera brings a field deployable platform based around a solid state nanopore sensor to quantitative NAT, serology and urinalysis testing.
Anna	Artese	Net4Science academic Spin-Off, Università degli Studi "Magna	Italy	artese@unicz.it	Net4Science would be useful for the rational drug design of new potential antiviral agents as a link between public and private research institutions.

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
		Græcia" di Catanzaro			
Emelia	Assar	public health england	porton down	emelia.assar@phe.gov.uk	I have recently joined PHE NIS Business Development team
Zeynep	Atabay Taskent	atabay	Istanbul	zatabay@atabay.com	cov
Sigrid	Auweter	Smart Reporting GmbH	Germany	s.auweter@smartreporting.de	Develop reporting and decision support for fast and accurate analysis of COVID-19 profiles on CT/biopsy, in line with diagnostic criteria.
Giuseppe	Balistreri	University of Helsinki	Helsinki	giuseppe.balistreri@helsinki.fi	Virologist, high-content imaging, virus-cell interactions, genome-wide CRISPR screening, novel antiviral molecules
Anne	Balkema-Buschmann	Friedrich-Loeffler-Institut (FLI) Institute of Novel and Emerging Infectious Diseases	Germany	anne.buschmann@fli.de	The Friedrich-Loeffler-Institut is running animal facilities for small and large animals up to biosafety level 4. FLI staff has decades of experience in working with animal disease and zoonotic agents in a variety of relevant animal species. I am the person responsible for the maintenance of FLI's fruit bat colonies of two different species ( <i>Rousettus aegyptiacus</i> and <i>Eidolon helvum</i> ) that are available for challenge and pathogenesis studies. The transmissibility to domestic animals and wildlife species, as well as their potential role in the epidemiology of COVID-19 is one of our

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
					major interests and competences in the field of Sars-COV-2 research.
Robert	Bals	Saarland University	Germany	Robert.Bals@uks.eu	High throuput assays on differentiated airway epithelium for detection of novel antivirals.
Sofiane	Bennacer	Credo Diagnostics Biomedical	Singapore	s.bennacer@credodxbiomed.com	We have developed a 20 min COVID-19 RT-PCR test. It can be deployed without additional equipment in laboratories, ER, clinics, and even in airports and seaports.
Natalia	Beshchasna	Fraunhofer Institute for Ceramic Technologies and Systems	Germany	natalia.beshchasna@ikts.fraunhofer.de	IKTS develops (bio)sensors based on LTTC, glass, flexible substrates and printing technologies; works in the field of microfluidics, collaborates with companies in the area of in vitro diagnostics, aptamer development, microfluidic devices, precise electronics; currently works in two international Eureka consortiums developing aptamer-based biosensors.
Charles	Betz	Luxinnovation - National Innovation Agency	Luxembourg	charles.betz@luxinnovation.lu	Contact to national stakeholders (companies, public research, NGOs)
Jane	Boland	St George's, University of London	London	jboland@sgul.ac.uk	Administrative, legal, financial and project management experience
Luisa	Borgianni	Sclavo Vaccines Association	SIENA	borgianni@sclavo.org	Management, Dissemination and Impact assesment
Annalaura	Brai		Italy	al.brai@leaddiscoverysiena.it	Custom synthesis of compounds, internal library of antivirals

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Andrea	Calcagno	Unit of Infectious Diseases, Department of Medical Sciences, University of Torino	Italy	andrea.calcagno@unito.it	We are a Unit of Infectious Diseases currently admitting and following patients with infection by SARS-CoV-2. We have a strong pharmacological background and we are able to develop methods for measuring drugs PK in plasma and tissues. We therefore may contribute by enrolling patients and/or by performing PK/PD studies.
Marc	Centellas	Laboratorios Gebro Pharma, S.A.	Spain	marc.centellas@gebro.es	Gebro developed Duplaxil, a hydroxychloroquine 400mg film-coated tablets. This product inhibits key components of the coronavirus infection lifecycle.
Corentin	Chaboud	BIOASTER	France	Corentin.chaboud@bioaster.org	Rapid diagnostic test development, antigen/antibody development, industrial standards, IMI project experience.
Gael	Champier	ArkAb SAS	France	gael.champier@arkab.fr	ArkAb will develop Human chimeric mAbs for oral immunotherapy anti 2019-nCov (secretory IgA) and for immunodiagnosis (IgM, IgA and IgA).
Ming-Fu	Chang	National Taiwan University	Taipei	mfchang@ntu.edu.tw	We would like to develop rapid tests for COVID-19 patients.
Chien-Fu	Chen	National Taiwan University	Taiwan	stevechen@ntu.edu.tw	Develop COVID-19 rapid test platforms.
Florence	Chung	Inserm Transfert	France	florence.chung@inserm-transfert.fr	Project management - IP dissemination & exploitation

Name	Surname	Organisation	Country	e-mail address	Potential contribution to the project in terms of expertise, resources and activities.
Gregor	Cicchetti	Paul Scherrer Institute	Villigen	gregor.cicchetti@psi.ch	structural biology for biomedical applications
BENJAMIN	Cid-Bourié	GENERAL PHARMACEUTICAL COUNCIL OF SPAIN	MADRID	benjamincid@redfarma.org	KNOWLEDGE ABOUT FUTURE PUBLIC HEALTH CARE POLICIES REGARDING TREATMENT AND DIAGNOSTICS